GOLM1, golgi membrane protein 1, 51280

N. diseases: 100; N. variants: 3
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.010 AlteredExpression phenotype BEFREE Recent reports show that Golgi membrane protein 1 (GOLM1) is highly expressed in a variety of tumor cells, functions as a negative regulator of T cells and then promotes tumor progression. 29637008 2018
Leukocyte adhesion deficiency type 1
0.010 Biomarker disease BEFREE Knockdown of GOLM1 repressed the LAD cell proliferation. 29710483 2018
Secondary malignant neoplasm of lymph node
0.010 AlteredExpression disease BEFREE Clinically, NSCLC patients with high expression of GOLM1 had shorter overall survival (OS) and high GOLM1 expression in tumor samples was significantly related to malignant phenotype, such as lymph node metastasis and high tumor stage. 29637008 2018
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder
0.010 Biomarker disease BEFREE These results suggest that GP73 promotes bladder cancer invasion and metastasis by inducing the EMT through down-regulating WT1 levels and activating the TGF-β1/Smad2 signalling pathway. 29349903 2018
CUI: C1266002
Disease: Non-small cell carcinoma
Non-small cell carcinoma
0.010 AlteredExpression disease BEFREE Overexpression of golgi membrane protein 1 promotes non-small-cell carcinoma aggressiveness by regulating the matrix metallopeptidase 13. 29637008 2018
CUI: C1335302
Disease: Pancreatic Ductal Adenocarcinoma
Pancreatic Ductal Adenocarcinoma
0.010 AlteredExpression disease BEFREE The present study aimed to investigate the expression of GOLPH2 in pancreatic ductal adenocarcinoma (PDAC) tissues and examined the effects of GOLPH2 on the growth and migration of pancreatic cancer cells. 29344673 2018
CUI: C1608426
Disease: Compensated cirrhosis
Compensated cirrhosis
0.010 Biomarker disease BEFREE Receiver operating characteristic curve analysis demonstrated that serum GP73 had a good diagnostic potential for compensated cirrhosis regardless of etiology. 29256057 2018
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
0.010 AlteredExpression disease BEFREE The growth and motility of the PDAC cells was enhanced following overexpression of GOLPH2, whereas downregulating the expression of GOLPH2 impaired the growth, motility and tumorigenesis. 29344673 2018
CUI: C0015695
Disease: Fatty Liver
Fatty Liver
0.010 Biomarker disease BEFREE Consistent with these functional findings, GP73 blockage could alleviate tunicamycin-induced liver steatosis by reducing SREBPs activation. 29097707 2017
CUI: C0017638
Disease: Glioma
Glioma
0.010 Biomarker disease BEFREE We further demonstrated that activation of AKT is the driving force of GOLM1-promoted glioma progression. 29282077 2017
CUI: C1512409
Disease: Hepatocarcinogenesis
Hepatocarcinogenesis
0.010 Biomarker disease BEFREE Besides, this study provides a novel insight into the mechanism of hepatocarcinogenesis and a promising blueprint for miR-493-5p-GP73 axis-oriented treatment of HCC. 28419971 2017
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis
0.010 Biomarker disease BEFREE Consistent with these functional findings, GP73 blockage could alleviate tunicamycin-induced liver steatosis by reducing SREBPs activation. 29097707 2017
CUI: C3850141
Disease: Acute-On-Chronic Liver Failure
Acute-On-Chronic Liver Failure
0.010 AlteredExpression disease BEFREE Further ELISA analysis confirmed the significant up-regulation of GP73, MMR, OPN and down-regulation of ATIII, HPX, APO-CII in HBV-ACLF plasma samples (<i>p</i> < 0.01). 29270132 2017
CUI: C0877445
Disease: Candidemia
Candidemia
0.010 GeneticVariation disease BEFREE Among them, a cytokine QTL at the NAA35-GOLM1 locus markedly modulated interleukin (IL)-6 production in response to multiple pathogens and was associated with susceptibility to candidemia. 27376574 2016
CUI: C0004763
Disease: Barrett Esophagus
Barrett Esophagus
0.010 Biomarker disease BEFREE We demonstrate that the structure of the Golgi is fragmented and the intracellular localisation of GOLPH2 is altered in BO and oesophageal adenocarcinoma tissue. 26461057 2015
CUI: C0014852
Disease: Esophageal Diseases
Esophageal Diseases
0.010 Biomarker group BEFREE Cellular functions for GOLPH2 are currently unknown, therefore in this study we sought to investigate functional roles for this Golgi-associated protein in oesophageal disease. 26461057 2015
CUI: C0151517
Disease: Complete atrioventricular block
Complete atrioventricular block
0.010 Biomarker disease BEFREE In conclusion, serum GP73 was found to be correlated with liver pathological grading and staging in patients with CHB, and may be an effective indicator for the evaluation of disease progression. 25524053 2015
CUI: C0279628
Disease: Adenocarcinoma Of Esophagus
Adenocarcinoma Of Esophagus
0.010 Biomarker disease BEFREE We demonstrate that the structure of the Golgi is fragmented and the intracellular localisation of GOLPH2 is altered in BO and oesophageal adenocarcinoma tissue. 26461057 2015
CUI: C0546837
Disease: Malignant neoplasm of esophagus
Malignant neoplasm of esophagus
0.010 Biomarker disease BEFREE GOLPH2 is secreted by oesophageal cancer cells and GOLPH2 expression, cleavage and secretion facilitate cell migration and invasion. 26461057 2015
CUI: C0677984
Disease: Locally Advanced Malignant Neoplasm
Locally Advanced Malignant Neoplasm
0.010 Biomarker disease BEFREE Six genes were differentially expressed in patients with localized and locally advanced cancer (GOLM1, GBX2, XPO6, SSTR1, TOP2A and cell division cycle associated 5, CDCA5) and three genes (HOXC6, Cyclin-dependent kinase inhibitor 2A (CDKN2A) and MYC binding protein 2, E3 ubiquitin protein ligase, MYCBP2) in patients with a low vs. high Gleason grade/sum. 26408707 2015
CUI: C0279606
Disease: Childhood Hepatocellular Carcinoma
Childhood Hepatocellular Carcinoma
0.010 Biomarker disease BEFREE Effect of GP73 silencing on proliferation and apoptosis in hepatocellular cancer. 25170213 2014
CUI: C0279607
Disease: Adult Hepatocellular Carcinoma
Adult Hepatocellular Carcinoma
0.010 Biomarker disease BEFREE Effect of GP73 silencing on proliferation and apoptosis in hepatocellular cancer. 25170213 2014
CUI: C1861453
Disease: Pseudohyperkalemia Cardiff
Pseudohyperkalemia Cardiff
0.010 AlteredExpression disease BEFREE TGF-β1 and GP73 expression means were also higher in HCC patients than controls and CHC patients (P < 0.05). 24186850 2013
CUI: C0206624
Disease: Hepatoblastoma
Hepatoblastoma
0.010 AlteredExpression disease BEFREE The interleukin-6 (IL-6) family cytokines were tested for effects on GP73 mRNA and/or protein levels in human hepatoblastoma HepG2 cells. 23144154 2012
CUI: C0023903
Disease: Liver neoplasms
Liver neoplasms
0.010 AlteredExpression group BEFREE In the present study, we investigated the effect of Fut8 overexpression on GP73 production in the human hepatoma cell line Hep3B. 21503570 2011